Custom service
Peptide Target Binder Development
Develop peptide binders to a target from design through validated affinity
Teams come to this service when they need to develop peptide binders to a target from design through validated affinity. We typically start from in-silico pre-screening, add library or rational candidate generation where the application demands it, and close the loop with SPR/BLI affinity confirmation so the final validated binder set with Kd data behaves consistently across lots.
Design reviews are part of the schedule, not an extra. Sequence, spacer architecture and analytical strategy are signed off before the first synthesis run, which is why the 6–12 weeks timeline holds in practice.
Affinity maturation of weak starting hits
Binders for assay capture and blocking
Binder development against impure or unstable targets
Sequences where a recombinant expression route is objectively cheaper and faster
Release specification is fixed at quotation: standard >95% by HPLC, >98% for assay-critical material. Long chains (>60 residues) are additionally confirmed by MS/MS sequence coverage, and truncated-deletion species are quantified, not just summarized.
Service Highlights
- In-silico pre-screening as the default route, with library or rational candidate generation held as a proven fallback
- SPR/BLI affinity confirmation worked into the design where the application requires it
- Sequence difficulty analysis (aggregation risk, motif hazards) is done before synthesis, and the route is chosen around it
- Analytical confirmation of every intermediate before the final release
- Microwave-assisted coupling and double-coupling are applied automatically where the sequence demands them
- Validated binder set with Kd data delivered with a complete conjugation or synthesis certificate
How the work runs
Sequence analysis
Peptide Target Binder Development is analyzed for aggregation risk, motif hazards and puri?cation difficulty before a route is quoted.
Route selection
Fmoc solid-phase, fragment ligation or hybrid solution-phase is selected and documented.
Assembly
The chain is built with in-silico pre-screening applied where the sequence demands it, with double-coupling at hazard sites.
Cleavage & crude QC
Crude material is characterized so purification targets are set on data, not hope.
Purification
RP-HPLC (and ion-exchange where needed) delivers the agreed purity; fractions are pooled on MS confirmation.
Release
Validated binder set with Kd data is documented with the full analytical package and released.
Specifications & timeline
- Turnaround
- 6–12 weeks
- Typical scale
- 0.1 mg – 10 g per sequence
- Chemistry options
- in-silico pre-screening; library or rational candidate generation; SPR/BLI affinity confirmation
- Deliverable
- Validated binder set with Kd data
- QC package
- HPLC purity, ESI/MALDI MS, MS/MS confirmation for long chains
- Shipping
- Ambient with desiccant; blue ice for modified or sensitive peptides
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.